Welcome to our dedicated page for EIDOS THERAPEUTICS news (Ticker: EIDX), a resource for investors and traders seeking the latest updates and insights on EIDOS THERAPEUTICS stock.
This page contains historical news coverage for Eidos Therapeutics Inc (EIDX), a clinical-stage biopharmaceutical company that focused on developing treatments for transthyretin amyloidosis before its acquisition by BridgeBio Pharma. Eidos Therapeutics no longer operates as an independent public company.
The news archive documents Eidos's journey as a rare disease therapeutics developer, including updates on its lead drug candidate AG10, clinical trial progress, and regulatory milestones. TTR amyloidosis, the company's primary therapeutic target, represents a serious progressive disease affecting cardiac and neurological function, making the company's development efforts particularly relevant to patients and the broader rare disease community.
Historical news items cover clinical data readouts, scientific conference presentations, partnership discussions, and corporate developments that shaped the company during its time as a publicly traded entity. This archive provides valuable context for understanding the evolution of TTR amyloidosis therapeutics and the events leading to Eidos's acquisition.
For current news on the ongoing development of Eidos's former pipeline assets, including AG10, investors and researchers should follow BridgeBio Pharma (BBIO), which now owns and continues development of these programs. Bookmark this page for reference to Eidos Therapeutics' historical news coverage and corporate timeline.
Eidos Therapeutics reported its Q3 2020 financial results, revealing a net loss of $30.2 million, or $0.79 per share, compared to a net profit of $6.9 million in Q3 2019. The increase in losses is attributed to rising R&D and administrative expenses, totaling $22.6 million and $7.0 million respectively. The company completed enrollment in its Phase 3 ATTRibute-CM clinical study for acoramidis, anticipating top-line results by late 2021 or early 2022. Eidos also announced a merger agreement with BridgeBio Pharma, with expected closing in Q1 2021.
Eidos Therapeutics (Nasdaq: EIDX) announced the addition of two independent directors, Suzanne Sawochka Hooper and Duke Rohlen, to its board. Hooper, a former executive at Jazz Pharmaceuticals, brings extensive leadership experience, while Rohlen has a strong background in medical technology entrepreneurship. They replace outgoing board members Rajeev Shah and Eric Aguiar. The company continues to advance its Phase 3 clinical trial for acoramidis, a potential best-in-class treatment for transthyretin amyloidosis (ATTR), which affects over 400,000 patients worldwide.
Eidos Therapeutics (EIDX) reported Q2 2020 financial results, showing a net loss of approximately $28.8 million ($0.76 per share), up from $14.1 million ($0.39 per share) in Q2 2019. Cash and equivalents stood at $174.8 million. The rise in losses was attributed to increased R&D expenses for acoramidis (formerly AG10), totaling $17.9 million, and general administrative costs reaching $10.3 million. Eidos plans to complete patient enrollment for its Phase 3 trial in ATTR-CM by H1 2021 and initiate ATTR-PN trials in H2 2020.
